The European Position Paper on Rhinosinusitis and Nasal Polyps 2020 is the update of similar evidence based position papers published in 2005 and 2007 and 2012. The core objective of the EPOS2020 guideline is to provide revised, up-to-date and clear evidence-based recommendations and integrated care pathways in ARS and CRS. EPOS2020 provides an update on the literature published and studies undertaken in the eight years since the EPOS2012 position paper was published and addresses areas not extensively covered in EPOS2012 such as paediatric CRS and sinus surgery. EPOS2020 also involves new stakeholders, including pharmacists and patients, and addresses new target users who have become more involved in the management and treatment of rhinosinusitis since the publication of the last EPOS document, including pharmacists, nurses, specialised care givers and indeed patients themselves, who employ increasing self-management of their condition using over the counter treatments. The document provides suggestions for future research in this area and offers updated guidance for definitions and outcome measurements in research in different settings. EPOS2020 contains chapters on definitions and classification where we have defined a large number of terms and indicated preferred terms. A new classification of CRS into primary and secondary CRS and further division into localized and diffuse disease, based on anatomic distribution is proposed. There are extensive chapters on epidemiology and predisposing factors, inflammatory mechanisms, (differential) diagnosis of facial pain, allergic rhinitis, genetics, cystic fibrosis, aspirin exacerbated respiratory disease, immunodeficiencies, allergic fungal rhinosinusitis and the relationship between upper and lower airways. The chapters on paediatric acute and chronic rhinosinusitis are totally rewritten. All available evidence for the management of acute rhinosinusitis and chronic rhinosinusitis with or without nasal polyps in adults and children is systematically reviewed and integrated care pathways based on the evidence are proposed. Despite considerable increases in the amount of quality publications in recent years, a large number of practical clinical questions remain. It was agreed that the best way to address these was to conduct a Delphi exercise . The results have been integrated into the respective sections. Last but not least, advice for patients and pharmacists and a new list of research needs are included. The full document can be downloaded for free on the website of this journal: http://www.rhinologyjournal.com.

中文翻译：

---

2020 年欧洲鼻窦炎和鼻息肉立场文件。

2020 年欧洲鼻窦炎和鼻息肉立场文件是对 2005 年、2007 年和 2012 年发表的类似循证立场文件的更新。EPOS2020 指南的核心目标是提供修订的、最新的和明确的循证建议以及 ARS 和 CRS 中的综合护理途径。EPOS2020 提供了自 EPOS2012 立场文件发表以来八年来发表的文献和开展的研究的更新，并解决了 EPOS2012 未广泛涵盖的领域，例如儿科 CRS 和鼻窦手术。EPOS2020 还涉及新的利益相关者，包括药剂师和患者，并针对自上次 EPOS 文件发布以来更多参与鼻窦炎管理和治疗的新目标用户，包括药剂师、护士、专业的护理人员，甚至是患者本身，他们使用非处方治疗来增加对自身病情的自我管理。该文件为该领域的未来研究提供了建议，并为不同环境下研究的定义和结果测量提供了更新的指南。EPOS2020 包含有关定义和分类的章节，我们在其中定义了大量术语并指出了首选术语。提出了基于解剖学分布将 CRS 分为原发性和继发性 CRS 以及进一步分为局部和弥漫性疾病的新分类。关于流行病学和诱发因素、炎症机制、面部疼痛（鉴别）诊断、过敏性鼻炎、遗传学、囊性纤维化、阿司匹林加重呼吸道疾病、免疫缺陷、过敏性真菌性鼻窦炎与上下气道的关系。关于小儿急慢性鼻窦炎的章节被彻底改写。对成人和儿童伴有或不伴有鼻息肉的急性鼻窦炎和慢性鼻窦炎治疗的所有现有证据进行了系统评价，并提出了基于证据的综合护理途径。尽管近年来高质量出版物的数量显着增加，但仍然存在大量实际的临床问题。大家一致认为，解决这些问题的最佳方法是进行 Delphi 练习。结果已整合到各个部分。最后但同样重要的是，还包括对患者和药剂师的建议以及新的研究需求清单。